Roches fenebrutinib is the first investigational medicine in over a decade that reduces disability progression in primary progressive multiple sclerosis (PPMS)
Late-breaking Phase III FENtrepid results presented at ACTRIMS show investigational fenebrutinib met…
Lexicon Announces Closing of Approximately $94.6 Million Public Offering and Concurrent Private Placement
February 06, 2026 17:17 ET | Source: Lexicon Pharmaceuticals, Inc. THE WOODLANDS,…
Laughland Teeth Whitening Kit: Ingredients, Disclosures, and What Consumers Are Researching in 2026
New York, NY, Feb. 06, 2026 (GLOBE NEWSWIRE) -- Disclaimer: This article…
GaraHerb Supplement Facts, Ingredient Label Details, and Product Disclosures: A 2026 Informational Overview of Male Enhancement Supplement Options
New York, NY, Feb. 06, 2026 (GLOBE NEWSWIRE) -- Disclaimer: This article…
Cannabix Technologies announces Non-Brokered LIFE Private Placement
February 06, 2026 19:00 ET | Source: Cannabix Technologies Inc. NOT FOR…
LuminEye Nano-Drops Product Information Updated as Consumer Interest in Eye Health Supplement Options and Vision Support Alternatives Grows in 2026
New York, NY, Feb. 06, 2026 (GLOBE NEWSWIRE) -- Disclaimer: This article…
HUTCHMED to Announce 2025 Final Results
February 06, 2026 03:30 ET | Source: HUTCHMED (China) Limited HONG KONG…
VALNEVA Declaration of shares and voting rights: January 31, 2026
VALNEVA Declaration of shares and voting rights January 31, 2026__________________________________________________________________________________________ Company name:…
Coloplast A/S – Interim Financial Report, Q1 2025/26
2025/26Interim financial results, Q1 2025/261 October 2025 - 31 December 2025 Coloplast…
